Hari M. Dhingra

2.9k total citations · 1 hit paper
31 papers, 2.2k citations indexed

About

Hari M. Dhingra is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Hari M. Dhingra has authored 31 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in Hari M. Dhingra's work include Lung Cancer Research Studies (16 papers), Lung Cancer Treatments and Mutations (12 papers) and Neuroendocrine Tumor Research Advances (6 papers). Hari M. Dhingra is often cited by papers focused on Lung Cancer Research Studies (16 papers), Lung Cancer Treatments and Mutations (12 papers) and Neuroendocrine Tumor Research Advances (6 papers). Hari M. Dhingra collaborates with scholars based in United States, United Kingdom and Switzerland. Hari M. Dhingra's co-authors include Frank V. Fossella, Joe B. Putnam, Jack A. Roth, Michael Ryan, William K. Murphy, Waun Ki Hong, E. Neely Atkinson, R. Komaki, J. S. Lee and Martin Chasen and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Hari M. Dhingra

30 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer

1994 804 citations Jack A. Roth, Frank V. Fossella et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hari M. Dhingra United States	16	1.7k	1.3k	251	225	219	31	2.2k
Jean Louis Pujol France	16	1.3k 0.8×	1.1k 0.9×	281 1.1×	140 0.6×	122 0.6×	35	1.8k
R. B. Livingston United States	21	820 0.5×	1.1k 0.9×	251 1.0×	158 0.7×	203 0.9×	65	1.6k
Claude Denham United States	7	2.6k 1.5×	985 0.8×	353 1.4×	194 0.9×	280 1.3×	10	3.0k
Charalambos Kouroussis Greece	18	752 0.4×	1.0k 0.8×	264 1.1×	143 0.6×	188 0.9×	49	1.5k
G. Bureau Belgium	18	861 0.5×	1.1k 0.8×	335 1.3×	95 0.4×	64 0.3×	42	1.4k
P Libert Belgium	15	837 0.5×	1.0k 0.8×	309 1.2×	92 0.4×	59 0.3×	28	1.3k
Paul E. Van Schil Belgium	19	2.0k 1.2×	1.2k 1.0×	327 1.3×	436 1.9×	202 0.9×	68	2.7k
Myung‐Ju Ahn South Korea	20	990 0.6×	792 0.6×	250 1.0×	175 0.8×	159 0.7×	75	1.5k
Colum J Smith Canada	14	1.5k 0.9×	869 0.7×	206 0.8×	219 1.0×	406 1.9×	20	2.1k
A. Ceribelli Italy	10	1.3k 0.7×	1.1k 0.9×	276 1.1×	218 1.0×	43 0.2×	27	1.7k

Countries citing papers authored by Hari M. Dhingra

Since Specialization

Citations

This map shows the geographic impact of Hari M. Dhingra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hari M. Dhingra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hari M. Dhingra more than expected).

Fields of papers citing papers by Hari M. Dhingra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hari M. Dhingra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hari M. Dhingra. The network helps show where Hari M. Dhingra may publish in the future.

Co-authorship network of co-authors of Hari M. Dhingra

This figure shows the co-authorship network connecting the top 25 collaborators of Hari M. Dhingra. A scholar is included among the top collaborators of Hari M. Dhingra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hari M. Dhingra. Hari M. Dhingra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dhingra, Hari M., et al.. (2025). Comparative Study of Machine Learning and Deep Learning Models for Early Prediction of Ovarian Cancer. IEEE Access. 13. 87336–87349.

Hayes, Teresa G., et al.. (2005). Phase I trial of oral talactoferrin alfa in refractory solid tumors. Investigational New Drugs. 24(3). 233–240. 80 indexed citations

Varadhachary, Gauri R., et al.. (2004). Oral recombinant human Lactoferrin (rhLF) slows tumor growth in metastatic NSCLC and other advanced incurable cancers: Results of a Phase II study. Journal of Clinical Oncology. 22(14_suppl). 3140–3140. 4 indexed citations

Massarweh, Suleiman & Hari M. Dhingra. (2001). Unusual Sites of Malignancy. Journal of Clinical Oncology. 19(5). 1574–1575. 23 indexed citations

Roth, Jack A., E. Neely Atkinson, Frank V. Fossella, et al.. (1998). Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 21(1). 1–6. 320 indexed citations

Roth, Jack A., Frank V. Fossella, R. Komaki, et al.. (1994). A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 86(9). 673–680. 804 indexed citations breakdown →

Murphy, William K., Frank V. Fossella, R Winn, et al.. (1993). Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer. JNCI Journal of the National Cancer Institute. 85(5). 384–388. 373 indexed citations

Umsawasdi, Theera, et al.. (1991). A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy. Cancer. 67(1). 48–54. 10 indexed citations

Dhingra, Kapil, et al.. (1991). A phase I trial of recombinant alpha-2a Interferon (Roferon-A) with weekly cisplatinum. Investigational New Drugs. 9(1). 37–39. 13 indexed citations

10.

Holoye, Paul Y., et al.. (1990). Intrapleural etoposide for malignant effusion. Cancer Chemotherapy and Pharmacology. 26(2). 147–150. 17 indexed citations

11.

Holoye, Paul Y., Marion J. McMurtrey, C. F. Mountain, et al.. (1990). The role of adjuvant surgery in the combined modality therapy of small-cell bronchogenic carcinoma after a chemotherapy-induced partial remission.. Journal of Clinical Oncology. 8(3). 416–422. 8 indexed citations

12.

Glisson, Bonnie S., Hari M. Dhingra, William K. Murphy, et al.. (1990). Ifosfamide with Mesna Uroprotection in the Management of Lung Cancer. American Journal of Clinical Oncology. 13(2). 148–155. 10 indexed citations

13.

Murphy, William K., et al.. (1989). Primary chemotherapy of brain metastasis in small-cell lung cancer.. Journal of Clinical Oncology. 7(7). 916–922. 80 indexed citations

14.

Umsawasdi, Theera, Manuel Valdivieso, Daniel J. Booser, et al.. (1989). Weekly doxorubicinversus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer. 64(10). 1995–2000. 18 indexed citations

15.

Holoye, Paul Y., David Carr, Hari M. Dhingra, et al.. (1988). Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma. Investigational New Drugs. 6(3). 217–218. 5 indexed citations

16.

Umsawasdi, Theera, Manuel Valdivieso, H. Thomas Barkley, et al.. (1988). Combined chemoradiotherapy in limited-disease, inoperable non-small cell lung cancer. International Journal of Radiation Oncology*Biology*Physics. 14(1). 43–48. 11 indexed citations

17.

Lee, Jin S., Hari M. Dhingra, Delia F. Chiuten, et al.. (1987). Phase II Pilot Study with Cisplatin, Etoposide, and Continuous-Infusion 5-Fluorouracil in Metastatic Non-small Cell Lung Cancer. American Journal of Clinical Oncology. 10(6). 512–514. 9 indexed citations

18.

Laberge, Francis, Herbert A. Fritsche, Theera Umsawasdi, et al.. (1987). Use of carcinoembryonic antigen in small cell lung cancer prognostic value and relation to the clinical course 1. Cancer. 59(12). 2047–2052. 25 indexed citations

19.

Dhingra, Hari M., Manuel Valdivieso, David Carr, et al.. (1985). Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 3(2). 176–183. 67 indexed citations

20.

Valdivieso, Manuel, Theera Umsawasdi, Gary Spitzer, et al.. (1984). Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer. American Journal of Clinical Oncology. 7(3). 241–244. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact